Takeda Pharmaceutical Co Ltd ADR
Price & Volume
Stats
See more52W Range | $12.99-$18.50 |
Market Cap | $58.3B |
Shares Short | 7M |
Financials
See moreRevenue (12 Mos) | $4.4T |
Revenue Growth (YoY) | 4.2% |
Gross Profit (12 Mos) | $2.9T |
Diluted EPS | $0.23 |
News
See moreYahoo Finance • 4 days ago
H.C. Wainwright Raises Protagonist Therapeutics, Inc. (PTGX) Target to $117, Reiterates Buy
Yahoo Finance • 5 days ago
U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Takeda’s Oveporexton (TAK-861) as a Potential First-in-Class Therapy for Narcolepsy Type 1
Yahoo Finance • 13 days ago
Is Takeda’s Upgraded FY2025 Outlook And New PID Therapy Altering The Investment Case For Takeda (TSE:4502)?
Yahoo Finance • 2 months ago
Blending Data and Local Knowledge To Enable Sustainable Outcomes
About
CEO | Mr. Christophe Weber |
CFO | Mr. Milano Furuta |
Address | 1-1, Nihonbashi-Honcho 2-chome, Tokyo, Japan, 103-8668 |
Sector | Healthcare |
Industry | Drug Manufacturers - Specialty & Generic |
Full-Time Employees | 47,455 |
